Equashield logo black

FDA Clearance of EQUASHIELD® Syringe Unit for Full Volume Use

We are thrilled to announce that the EQUASHIELD® Syringe Unit has received additional FDA clearance for full volume use1. This achievement marks a significant milestone for our company, as we celebrate our fifth consecutive year of being the most used CSTD in the USA. We firmly believe that our innovative product design will revolutionize the way hazardous drugs are handled, offering unparalleled safety and efficiency.

Compared to Other Syringes on the Market 

Many institutions adhere to guidelines that limit the fill volume of standard syringes to three-quarters when handling hazardous drugs (OSHA, ASHP) to prevent loss of the plunger2,3. Our EQUASHIELD® Syringe Unit, however, eliminates this risk, preventing vapor escape and plunger contamination. The design allows you to use the most accurate syringe size possible for compounding and administration4.  

Introducing the Unique EQUASHIELD® Syringe Unit 

EQUASHIELD® Syringe Unit, a barrier type CSTD, stands out from its competitors with its one-of-a-kind closed-back design and bonded connector. This innovative design effectively eliminates more routes of hazardous drug exposure than alternate systems, preventing vapor escape and plunger contamination. The encapsulated plunger of the EQUASHIELD® Syringe Unit cannot be detached from the barrel, ensuring the safe usage of the entire Syringe Unit volume.

Benefits of Full-Volume Use 

Full-volume use of the EQUASHIELD® Syringe Unit has multiple benefits:  

  • Cost reduction: Utilize fewer syringes for compounding and administering a dose, thanks to the full volume utilization of each syringe. In combination with the full volume use and largest EQUASHIELD® syringes being 35mL and 60mL, contribute to major cost savings compared to regular off the shelf syringes.   
  • Reduced strain: Experience less strain due to minimized repetitive motion.
  • Save time: Compound and prepare doses more efficiently with fewer syringes, leading to significant time savings. 
  • Waste reduction: Decrease waste in both compounding and administering doses with optimized syringe usage. 

Consider the following example to illustrate the potential cost savings:

EQUASHIELD significantly reduces syringe usage, streamlining the process with just 1 Syringe Unit. In contrast to other CSTD’s that often require 2 syringes + 2 or more injectors/connectors for the most common drug. This streamlining ensures efficiency and cost-effectiveness in your drug handling practices.

A Safer and More Efficient Solution 

The EQUASHIELD® Syringe Unit was created with your safety at the forefront of our minds. We understand the potential risks involved with handling hazardous drugs, and we believe that our unique design offers a safer solution. The FDA clearance is a testament to the commitment we have in ensuring our products are safe and reliable.

In addition to safety, the EQUASHIELD® Syringe Unit offers efficiency. By allowing full-volume use, we help streamline your processes, reducing waste and maximizing your resources. This results in a cost-effective solution for your medication compounding and administrating needs.

Embrace Safety and Efficiency with the EQUASHIELD® Syringe Unit 

For over a decade, through our innovative design and commitment to safety, we have created a product that stands out in the industry. The EQUASHIELD® Syringe Unit is more than just a syringe; it’s a safe, efficient, and cost-effective solution for handling hazardous drugs. As we mark this FDA clearance, we look forward to continuing to provide you with the highest quality products that meet your needs.

Evaluation of The Sterility of Single-use Vials Undergoing Multiple Access Following Application of a Closed System Transfer Device (CSTD)


  • Closed system transfer devices (CSTD) such as Cyto-Set® (1), PhaSeal® (2), and Equashield® (3) are designed to reduce hazardous drug exposure from preparation to administration (4)
  • While these devices protect staff and have been provided an ONB designation by the FDA, as aclosed system they can also minimize microbial contamination because the devices are airtight and leak-proof, potentially preventing microbial ingress.
  • Equashield® was rated favourably in terms of ease of use and therefore used as the chosen CSTD for this study (4,6)
  • Objectives
  • We undertook this study to test whether attaching Equashield® adaptors to simulated single-use vials (Tryptic Soy Broth 20 mL vials):
  • Could prevent or minimize microbial contamination and extend the “use-by” date following multiple withdrawals under extreme-use-conditions
  • Could verify the results of previously published data (5) applied to real-world conditions with multiple staff members and multiple areas at Sunnybrook Health Sciences Centre Pharmacy


  • Each lot of TSB growth medium was secondarily tested as a positive control by inoculation with less than 10-2 of S. epidermidis ATC 12228, incubation at 37oC and review at 24 and 48 hours afterwards
  • As a negative control, an unopened vial of TSB 20 mL from each lot was incubated for the duration of the study

Figure 1


  • All positive control vials demonstrated growth within 48 hours
  • All negative control vials showed no growth throughout the study
  • All accessed vials remained sterile following storage at room temperature for 5 days and subsequent incubation for 14 days
  • None of the 192 vials (B & C) accessed 1440 times showed evidence of contamination. The 95% confidence interval of the contamination rate is 0.000 to 0.035%
  • None of 96 vials with CSTD attached but without broth removed demonstrated contamination

Table 1

Cost saving implications

  • Annual drug wastage in the cancer centre pharmacy, adhering to chemical stability and preparation in an ISO Class 5 environment, but not discarding partial vials after 6 hr as per USP<797> was ~$185,000 in 2014/15. This represents ~1% of drug expenditures. 
  • Annual estimates of drug wastage in 2015/16, abiding USP<797> would be in excess of $2.7M. 
  • If we were to use a CSTD on every single use vial in our system, the drug cost savings to our system is estimated to exceed $2.5M annually. 
  • The incremental cost of the CSTD within the outpatient oncology program is estimated at $400,000 annually, based on drug expenditures of $20.4M and approximately 25,000 patient treatment visits.
  • Net cost savings would be ~$2.1M


  • Attachment of a CSTD adapter to single-use
    vials within an ISO-5 environment has the
    ability to maintain sterility following multiple
  • These results were consistent when the vials
    were exposed to continuous ISO 5 air quality
    and when exposed to poorer than ISO 5 air
    quality (Laminar air flow hood off)
  • These results remained consistent in the
    setting of multiple operators following training
    on the use of the CSTD

Figure 2

Economic impact of extending the beyond-use date of chemotherapy single-dose vials through the use of a closed-system transfer device


  • The United Stites Pharmacopeia Chapter <797> standards state that single-dose vials (SDV) must be discarded 6 hours after the first vial access if accessed and kept in ISO class 5 air conditions, otherwise the vial should be discarded after 1 hour
  • The purpose of this standard is to decrease the potential for bacterial contamination of medications. but this mandate leads to the waste of high-cost, chemically stable drugs
  • The Equashield® closed-system transfer device (CSTD) was shown to prevent microbial contamination of preservative-free SDV for 9 days after being accessed 10 times over a 7 day period? and consequently the FDA approved extending the beyond-use date (BUD) of SDV to 7 days through the use of the Equashield® CSTD in May 2014’
  • The Mount Sinai Hospital (MSH) has been using the Equashield® CSTD for the preparation and administration of hazardous drugs since 2011, and recently implemented BUD of chemo.biotherapy SDV in concordance with the recent FDA approval
  • Our one month cost analysis study in 2013 estimated a potential cost savings of more than $20,000 per month by extending the BUD of SDV chemo/biotherapy to 7 days at our institution


To assess the cost savings of extending the BUD of SDV of chemo/biotherapeutic agents through the use of the Equashieldt® CTSD

  • Primary objectives
    • To assess actual chemobiotherapy wastage: cost of chemobiotherapy discarded after implementing BUD of SDV
    • To assess potential chemobiotherapy wastage: cost of chemobiotherapy that would have been discarded if BUD of SDV was not implemented
  • Secondary objectives
    • Total number parenteral chemobiotherapy preparations compounded
    • Estimated cost of Equashieldt products used
    • The combined cost of wasted chemobiotherapy and Equashiel® products


  • A prospective economic analysis of all discarded liquid SDV of chemo/biotherapeubc agents from October 1st to October 30th 2014 (30-day study period) was performed at the MSH
  • Wasted amount of the 28 eligible chemobiotherapeutic agents for the study (table 1) were documented on a daily basis
  • The potential wastage of medications that would have been discarded if the vials were not reused for 7 days was also recorded
  • 340B price was used for ambulatory use and non-340B price was used for inpatient use for this cost savings analysis


  • Top six medications that represented the most cost savings were pegaspargase, rituximab, ipdimumab, bevacizumab, ramucirumab, and panitumumab
  • Implementation of BUD of chemoibiotherapy SDV using Equashield® CSTD allowed for a significant cost savings of $44 192 during the one month study period, translating to an estimated cost savings of approximately $530,000 annually
  • While implementing Equashield® CSTD represented an increase in annual expenditures of about $235,000, the resulting net cost savings by implementing BUD using this device ($530,000.’year) not only offset the cost of CTSD, but also resulted in a significant cost savings to our institution


  • Cost analysis using a longer study period (3-6 months) will represent more accurate estimated annual cost savings


  • Due to the short study penod (30 days), chemo/biotherapeutic agents used during this study penod may not represent those used throughout the year
  • BUD of chemo/biotherapy was implemented before the study period, therefore, our study included partiaty used vials that were initially opened before the study period, leading to potential underestimation of our cost savings


Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation

Tables 1-2

Figure 1

A 7 Days Microbial Ingress Test of Single Use Vials Utilizing the EQUASHIELD® Closed System Drug Transfer Device


Four groups of vials containing growth media were accessed with 770 Equashield® syringes. Each vial was accessed 10, 7 and 5 times respectively during 7 days using the Equashield® CSTD and 4ml were drawn off each time.

Before each of the 770 accesses, the access membranes of Equashield® Vial Adaptors were inoculated with (>103 CFU) with gram positive or gram negative bacteria respectively and were left to settle during ½ an hour on the membrane. Initially the Vial Adaptors were spiked onto the media-filled vials two days earlier and incubated, resulting in a total of 9 days of testing, from first spiking to last access, and a total of 770 tested Equashield® Syringes and vial accesses.

The tested vials were incubated once again after the 9 days of testing and examined to demonstrate the ability of the Equashield® CSTD to prevent vial contamination during 7 days of use. To further increase the challenge and the extreme use conditions, approximately a third of the tested Equashield® devices were old expired products.


All tested media-filled vials were negative for growth of any microorganisms.


Equashield® is a Closed System Transfer Device (CSTD) for the preparation and administration of hazardous drugs and it is cleared under FDA’s product code ONB for “closed antineoplastic and hazardous drug reconstitution and transfer systems”. It complies with NIOSH’s definition: “A drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system” 2.

As a CSTD that is designated for working with hazardous drugs, the compliance of Equashield® with especially the second part of NIOSH’s definition2 has been extensively tested in clinical and scientific studies and proven to be compliant, namely: “mechanically prohibits the escape of hazardous drug or vapor concentrations outside the system”. In order to achieve full closure of the Equashield® CSTD and contamination free connections, unprecedented mechanisms and design features were incorporated into the CSTD, which in turn created a natural advantage for the CSTD over conventional systems and methods, whereby the risk of the transfer of microbial contaminants into the system is minimized. In another aspect, the United States Pharmacopeia (USP) Chapter 797 standards1 mandate that singleuse or non-preserved drugs must be discarded 6 hours after first vial access, if the vial is accessed and remains in ISO class 5 air conditions, otherwise it must be discarded after 1 hour. The purpose of this USP standard1 is to provide patient protection by limiting the impact potential of any microbial contamination of the drug. On the other hand, it creates significant waste of partially used viable drugs, which in turn, increase financial expenditure. This includes the high-cost drugs which are discarded in spite of the fact that the majority of them remain chemically stable for days and weeks.

Published economical surveys demonstrate the obvious saving potential of the wasted drugs (in $Millions) if CSTDs can be proven capable of prohibiting the transfer of microbial contaminants into the drug vial to maximize the utilization of the drug. Furthermore, such savings can also finance the cost of the CSTDs.

The Phaseal® CSTD (Becton & Dickinson) has demonstrated the potential to prevent microbial ingress in vials up to 7 days in the following studies: “Utility of the PhaSeal Closed System Drug Transfer Device”, Derek M. McMichael et al., Am J Pharm Benefits. 2011;3(1):9-163; and “Second Look at Utilization of a Closed-System Transfer Device (PhaSeal)”, E. Thomas Carey et al., Am J Pharm Benefits. 2011;3(6):311-3184.

Basically in these studies3,4, vials containing growth media were accessed 5 times during 7 days and each time a transfer of a small portion from the vial content took place using the Phasealsup® CSTD under ISO 5 air conditions. Membrane disinfections and other standard aseptic techniques were used as well. The vials, simulating the drugs, were incubated after the 7 days of testing and examined to demonstrate the ability to prevent vial contamination during 7 days of use.

Pseudomonas Aeruginosa

Klebsiella pneumoniae

Staphylococcus aureus


The aim of the current study was to perform a significantly more extreme-use-conditions test than worse conditions expected in hospital pharmacy settings and worse than conditions of the above referenced previous studies3,4 , thus assessing the ability of the Equashield® CSTD to prevent the contamination of parenteral drug products during 7 days of use.


The challenge procedure consisted of inoculating the access membrane surface of multiple test article replicates of the Equashield® Vial Adaptor with gram positive or gram negative bacteria respectively, allowing the challenge to act and dry during ½ an hour, disinfecting the Vial Adaptor with a 70% isopropyl alcohol (IPA) pad, allowing the IPA to dry, connecting a new proprietary mating Equashield® 20ml Syringe Unit to the Vial Adaptor, and drawing a 4ml aliquot of sterile media (Soybean Casein Digest Broth) from the 50ml media-filled vial that the adapter was installed on. The test protocol specified a minimum inoculation titer of 103 colony forming units (CFU) per adaptor inoculation. The vials were divided into three similar groups and tested while the fourth group was added and tested in a replicated test one year later according FDA’s request. The first vial access was on day 1 at the commencement of the 9 day test, when the Vial Adaptors were spiked onto the sterile media-filled vials and then incubated two days long. Following their incubation and starting on day 3 the Vial Adaptors were each subjected to a total of 10 or 7 or 5 (group respectively) inoculation-disinfection-accesstransfer cycles over 7 calendar days, more specifically on days 3,4,5,8 and 9. The adapters were accessed once or twice each day, resulting in a total of 770 tested Equashield® Syringe Units with accesses and transfers.

The first three groups were tested with Staphylococcus aureus (American type Culture Collection ATCC #6538) and group four was tested in addition to S. aureus with Staphylococcus epidermidis, Klebsiella pneumoniae, Pseudomonas Aeruginosa.

To maintain equivalence with clinical use in hospital pharmacy, ISO 5 air conditions were used in this study and only one person for each group performed the testing without assistance. Furthermore, approximately a third of the tested Equashield® syringes and adapters were old products with expired use-dates. The tested vials were incubated for 2 days at 30°-35°C after the 9 days of testing and examined to demonstrate the ability of the Equashield® CSTD to prevent vial contamination during 7 days of use.


All tested media-filled vials were negative for growth of any microorganisms.


The results of the study confirmed that despite the extreme-use clinical conditions, the Equashield® CSTD prevented the microbial contamination of media-filled vials, which are more sensitive to contamination than drugs. The penetration of even one microorganism is suficient to create full contamination, and although the chances of bacteria survival and growth inside a hazardous drug vial are very slim, the media-filled vials used in the current study provided ample conditions for their multiplication and spreading.

To create even more extreme conditions, the vials in the current study were accessed up to 10 and 7 times during 7 days, whereas vials in previous studies3,4 were accessed only 5 times. Since the ability of a single connector to prevent contamination is naturally decreased with every additional connection and access, the number of connections gains increased significance in view of this non-linearly growing potential of contamination.

The repeated inoculation of the membrane with vivid bacteria before each of the vial accesses poses an extreme challenge to this primary microbial barrier; a challenge that does not exist (to such an extent) in a hospital routine setting, and that was also not included in the referenced studies3,4.

Without the special mechanisms and design features incorporated into the Equashield® connectors, the membrane alone would not be capable of such barrier performance. In fact, the doublemembrane connectors with their coring-free needles, special materials, and sequential guiding mechanisms, are responsible for creating the optimal conditions for satisfactory contamination prevention.

During the half hour that the bacteria were left to grow and settle on the membrane, the risk of them entering and settling in the openings or surface irregularities in the membrane, and subsequently moving into the vial or being moved by the penetrating needle, was obviously increased considerably in this study. In comparison, the FDA5,7 requires a minimum of only 1 minute for challenging microbial barriers. The ½ hour challenge time was chosen since at longer challenge the bacteria dries and becomes inactive.

The extreme conditions included the use of a significant number of Equashield® syringes and adapters that were old products with expired use-dates, whereby the sterility of their packaging may have been compromised, as often occurs with old products, and therefore the risk of contamination was much greater than expected from new products that were more recently packaged.

Unlike the conditions in many privileged hospital pharmacies and in previous studies3,4, no cleanroom was used in this study and the laminar flow hood had an open front without the glass screen (which normally improves the isolation of the hood). To maintain equivalence with routine working procedures and conditions in a hospital pharmacy, only one person performed the testing without assistance, and the device packages were opened inside the hood. Furthermore, unlike experienced personnel in hospital pharmacies and previous studies3,4, the operators were not proficient in using Equashield® and only received basic training at the commencement of the study.

The two types of vial accesses, namely: the spiking of the Vial Adaptor onto the vial and the access to the Vial Adaptor with the syringes, were purposely separated in this study. After spiking, the vials were incubated 2 days long and observed for turbidity before syringe accessing began. Both types of vial accesses were effective in preventing microbial ingress.

Furthermore, larger needles are known to cause greater damage and increase leak potential to barrier membranes than thinner needles; therefore Equashield® syringes with the larger needles were used in this study.

Thus, it could be argued that the current study not only reaffirms previous studies results, it also indicates that the solution in the vials remained uncontaminated when using the Equashield® CSTD in even more extreme conditions than may exist in hospital pharmacies, suggesting the possibility of practical benefit from the prevention of the microbial ingress feature, especially for single-use or nonpreserved drugs.


The current study unequivocally demonstrated that Equashield® CSTD is capable of preventing the microbial ingress and contamination of drugs over 7 days of use, which makes it a true CSTD, compliant with both aspects of NIOSH’s definitions2, namely: mechanically prohibiting the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.

Additionally, the standard disinfection procedure using IPA pads on Equashield® access ports was identified as adequate in preventing microbial ingress.

This ability of the CSTD, to provide extended microbial ingress prevention in extreme clinical conditions over a 7 day period, suggests improved patient protection in view of USP Chapter 7971 standards that currently limit the use of single-use non-preserved drugs to up to 6 hours in ISO class 5 air conditions.


The purpose of this research is to demonstrate the potential use of the Equashield Closed System Device. Its publication does not constitute and must not be construed as promotion or advice to deviate from, alter or otherwise exceed the guidelines, rules and standard related to aseptic preparations and techniques, or in any way deviate, alter or exceed the USE DATE or SHELF LIFE of the drugs. For any modification a user must comply with required steps and measures to change the established guidelines, rules and standard related to aseptic preparations and techniques, such as the procedural changes described in USP 797.

Study reports

  1. Group 1 test report #680210.1 April 05, 2013; 10 connections and accesses (report attached).
  2. Group 2 test report #680217.2 April 05, 2013; 7 connections and accesses (on sale).
  3. Group 3 test report #686405 May 07, 2013; 5 connections and accesses (on sale).
  4. Group 4 test report #13841-2 April 04, 2014; 5 connections and accesses (on sale).